KlegermanBlocking the creation of CHD4 protein may help increase efficiency of AML treatmentsThe Phase 2 study enrolled individuals with newly diagnosed AML, 60-75 years of age, who were able to tolerate intensive chemotherapy. This randomized study is designed to compare CPX-351 to the standard of care, commonly known as 7+3. In the 7+3 regimen, cytarabine is administered as a 7 day constant daunorubicin and infusion is administered on times 1, 2 and 3. CPX-351, containing both agents at a synergistic ratio, is infused over 90 minutes on days 1, 3 and 5. The primary endpoint of the analysis is complete remission rate. Secondary endpoints are duration of comprehensive remission, event free of charge survival, survival at 12 months, rate of stem cell transplant, 30, 60, and 90 day mortality, and safety and tolerability.We think that's because the study duration hasn't been prolonged; only two weeks at most with only a hint of disturbance at the very end,’ said Drake. ‘That's what we are centered on and concerned about.’ Ojile said the data collected could help to take care of patients with sleep problems potentially. ‘Data from extreme environments can often be used in normal circumstances,’ Ojile said. ‘We may find out something interesting about changes in the aquanauts' circadian rhythms, or the amount of time it takes because of their rest to normalize after surfacing could be noteworthy. The exciting matter is that people don't know what the extensive research will show. That's so why we're doing this.’..